Philadelphia, PA, February 12, 2013 – Scopolamine is an anticholinergic drug with many uses. For example, it prevents nausea, vomiting, and motion sickness.
However, scopolamine is re-emerging as an antidepressant, with recent studies showing that scopolamine can rapidly improve mood in depressed patients. In addition, in a new study published in Biological Psychiatry this month by Dr. Moriel Zelikowsky and colleagues at the University of California, Los Angeles, it may also be a possible treatment for anxiety disorders.
Exposure therapy, where the key goal is the elimination of fear through repeated 'safe' exposure to the threat, is commonly employed for the treatment of anxiety disorders. However, its effectiveness is diminished because humans and animals alike tend to be very sensitive to context, causing extinction learning to be dependent on the environment in which it occurs. This makes memories formed during extinction unstable. As a result, extinguished fears commonly return when people put themselves in new situations.
"Current research aimed at treating this problem either employs invasive, untranslatable methods or attempts to strengthen extinction learning rather than prevent relapse," explained senior author Dr. Michael Fanselow.
In an effort to solve this dilemma, Fanselow and his team took a novel theoretical approach. Employing an animal model of exposure therapy, they found they were able to disrupt the rats' contextual processing during extinction using low doses of scopolamine, which blocked the return of fear when the rats were exposed to both the original and a new context.
"This finding provides groundbreaking evidence that changing the nature of extinction learning, rather than its magnitude, can produce profound improvements in the prevention of relapse," added Fanselow.
Scopolamine also slowed the rate of extinction memory formation, which was overcome by adding training sessions. Taken together, these findings indicate that scopolamine may serve as a promising pharmacological adjunct to exposure therapy by improving one's resiliency to environmental changes.
"The emerging new uses for scopolamine are quite promising, although further research is needed," commented Dr. John Krystal, Editor of Biological Psychiatry. "These new data are a wonderful example of the capacity of translational neuroscience approaches to identify new uses for old medications."
The article is "Cholinergic Blockade Frees Fear Extinction from Its Contextual Dependency" by Moriel Zelikowsky, Timothy A. Hast, Rebecca Z. Bennett, Michael Merjanian, Nathaniel A. Nocera, Ravikumar Ponnusamy, and Michael S. Fanselow (doi: 10.1016/j.biopsych.2012.08.006). The article appears in Biological Psychiatry, Volume 73, Issue 4 (February 15, 2013), published by Elsevier.
Notes for Editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Michael S. Fanselow at +1 310 206 0247 or email@example.com, or Moriel Zelikowsky at firstname.lastname@example.org.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 129 Psychiatry titles and 16th out of 243 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2011 Impact Factor score for Biological Psychiatry is 8.283.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.